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Abstract
INTRODUCTION—There are few longitudinal studies of dementia in developing countries. We 
used longitudinal data from the Maracaibo Aging Study (MAS) to accurately determine the age- 
and sex-specific incidence of dementia in elderly Latin Americans.
METHODS—The DSM IV-R was used to diagnose dementia, which was classified as 
Alzheimer’s disease (AD), vascular dementia (VaD), or other. Age- and sex-specific incidence was 
estimated as the number of new cases of dementia divided by person-years of follow-up (p-y).
RESULTS—The incidence of all dementia diagnoses was 9.10 per 1000 p-y (95% CI 7.13–11.44; 
8026 total p-y), 5.18 for AD (95% CI 3.72–7.03; 7916 total p-y), and 3.35 for VaD (95% CI 2.19–
4.91; 7757 total p-y).
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DISCUSSION—Among MAS participants under 65 years of age, the incidence of dementia was 
higher than that of US whites. Among individuals over 65 years of age, the incidence was 
comparable to the mean of previous incidence estimates for other populations worldwide.
Keywords
Alzheimer’s disease; Epidemiology; Vascular dementia; Population-based; Hispanics
1. INTRODUCTION
The prevalence of dementia, a condition that disproportionately affects the elderly, is higher 
in most Latin American countries than in developed countries [1–3]. In 2015, approximately 
70.9 million Latin Americans were over 60 years of age. By 2030, that number will exceed 
121 million [4]. As such, the aging of the population puts an increasing number of 
individuals at risk. However, because prevalence reflects both the incidence and duration of 
disease, it is a limited measure of risk.
Incidence, the rate of occurrence of new cases, is a more useful measure of risk that is 
essential for evaluating temporal trends and for assessing the effects of preventative 
measures. The World Health Organization′s estimates of the incidence of dementia in 
developed countries ranged from 3.4 per 1000 person-years (p-y) at age 60–64 years to 99.4 
per 1000 p-y at >95 years [3]. There are only nine reports on the incidence of dementia in 
developing countries [5–12], all among those older than 65 years, and ranging from 3.2 per 
1000 p-y in India [11] to 21.85 per 1000 p-y in Nigeria [7]. None of these studies included 
complete neuropsychological and clinical assessments of all participants.
The goal of the present study is to provide an accurate estimate of dementia incidence in 
Venezuela, a developing country. Longitudinal data from the Maracaibo Aging Study (MAS) 
[13] were used to determine the age- and sex-specific incidence of dementia and its 
subtypes, Alzheimer’s disease (AD) and vascular dementia (VaD).
2. METHODS
2.1 Sample
The MAS is a population-based study of community-dwelling individuals aged 55 years and 
older who resided in downtown Maracaibo, Santa Lucia County, Venezuela, between 
January and August 1998 [14]. The MAS investigated cognitive, cardiovascular, nutritional, 
and social changes associated with aging, with a special emphasis on memory-related 
disorders. The baseline assessment was conducted between September 1998 and December 
2001. A total of 2453 out of 3765 residents ≥55 years of age underwent a standardized, 
multidimensional assessment of laboratory tests and their neuropsychological, 
neuropsychiatric, cardiovascular, and nutritional status. Of the 2453 assessed at the baseline 
evaluation, 198 participants were diagnosed as having dementia, and one participant was not 
assigned a Clinical Dementia Rating (CDR) [15]. Of the remaining 2254 assessed patients 
who composed the at-risk population, 411 (19.74%) died or relocated before the second 
evaluation, 28 (1.24%) were not available for any of the three reevaluation visits, and 122 
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(5.12%) declined to participate in the second evaluation. The 1693 participants who were 
reexamined at least once between 2001 and 2009 composed the sample for our study (Figure 
1).
The MAS was approved by the Institutional Review Board of the Cardiovascular Center at 
the University of Zulia in Maracaibo. Informed consent was obtained from each participant, 
or from a surrogate when appropriate, after they were provided with a complete explanation 
of the study.
2.2 Dementia Assessments and Diagnoses
The assessment and diagnostic procedures of the MAS have been previously described in 
detail [13]. Briefly, a social worker visited the home of each participant and conducted a 
family interview. Two social workers were available during the study period, both of whom 
received the same training, which consisted of practice interviews, roleplaying, visits to 
Santa Lucía with various members of the team (psychologists, physicians, historian) to 
understand the geography and history of the area, and biweekly feedback meetings. An 
informant (usually a spouse or adult child residing in the same home as the participant) was 
identified as knowledgeable about the participant’s daily activities and health issues. 
Information regarding changes in the abilities of the participant was collected using an 
adapted version of the Dementia Questionnaire [16], the third part of the Blessed Dementia 
Scale [17], and the Self-Maintaining and Instrumental Activities of Daily Living Scale [18], 
as well as information on the family history of dementia. All the participants were invited to 
undergo an in-depth neuropsychiatric evaluation (performed by a trained neurologist, 
psychiatrist, or internist), neuropsychological testing (by a psychologist), routine laboratory 
tests, and apolipoprotein E (APOE) genotyping [19, 20].
The neuropsychiatric assessment included a neurological examination, original and modified 
versions of the Mini-Mental State Examination (MMSE) [21, 22], the Blessed Orientation-
Memory and Concentration Test [17], the Schwab and England Scale to assess activities of 
daily living [23], the Zung Depression Scale [24], and the Neuropsychiatric Inventory [25].
The neuropsychological assessment included 17 tests for memory, abstract reasoning, 
orientation, constructional ability, language, and attention [22]: the Selective Reminding Test 
[26]; the Benton Visual Retention Test [27]; similarities from Wechsler Adult Intelligence 
Scale-Revised [28]; identities and oddities from Mattis [29]; five items from the Rosen 
Drawing Test [30]; the Boston Naming Test [31]; the Benton Multilingual Aphasia 
Examination [32]; comprehension and repetition from the Boston Diagnostic Aphasia 
Examination [31]; and cancellation (TMX and shapes).
Results of the neuropsychological tests were used as complementary information; diagnoses 
were not based on cutoff scores. The assessments were conducted on two consecutive 
mornings, usually at the Cardiovascular Center of the University of Zulia. If the participant 
could not leave their home, the assessment took place at the their residence.
Diagnoses of dementia were made by consensus during a conference of physicians, 
psychologists, and social workers, who discussed all ancillary information and followed the 
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diagnostic strategy developed for the Washington Heights-Inwood Columbia Aging Project 
in New York [22]. Subjects were classified as having dementia if they obtained a rating of 
Category 1 or higher on the CDR scale [15], and they had cognitive impairment resulting in 
a functional decline in their social or occupational activities from their previous level of 
functioning not explained by other conditions. Baseline and incident dementia diagnoses 
were classified as AD, VaD, or other dementia, based on standardized criteria for each 
illness in the Diagnostic and Statistical Manual of Mental Disorders (4th Edition) [33] and 
specific criteria for each dementia subtype [34–40]. Brain magnetic resonance scans 
(Phillips 1.5 T) were offered to all individuals with CDR 0.5 or higher, and to a randomly 
selected individuals for a total of 400 imaging studies. When available, neuroimages were 
included in the discussion, and they were mostly used for differential diagnosis. Dementia 
onset was estimated as the age at which the individual met the criteria for dementia, based 
on a systematic review of the chronological history of cognitive and functional changes. The 
consensus panel was blind to APOE genotype, previous CDR, and dementia type.
2.3 Data Analysis
The at-risk population consisted of MAS participants who were not diagnosed with 
dementia during the baseline assessment. For each participant, p-y was calculated as the 
number of years from baseline until (1) the time of dementia onset or (2) the time of 
completion of the last assessment at which the individual was found not to have dementia, 
whether they subsequently remained in the cohort, dropped out, or died. Incidence per 1000 
p-y was estimated as the number of new cases of dementia, divided by the at-risk p-y, 
multiplied by 1000 [41]. Confidence intervals (CIs) were calculated assuming a Poisson 
distribution for the number of cases within each age interval. Incidences were standardized 
using the Venezuelan population based on the 2001 national census [42] and the WHO 
world population data [43].
We added competing risk analyses suggested by the reviewer. In the methods section we 
added: “Because factors leading to nonparticipation could be linked to the same factors that 
affect dementia incidence [44], we conducted two types of analyses to assess the influence 
of dropouts (due to death, relocation, refusal or other cause of non participation) having 
developed dementia if they have stayed in the study. First, a sensitivity analysis was 
conducted that assumed that dementia incidence in nonparticipants was the same, 50%, 
100%, or 200% higher than the incidence in the assessed cohort. The second approach 
consisted of adjustment of incidence for competing risk due to death using a proportional 
subdistribution hazards model developed by Fine and Gray[45] and modified by Chang et al.
[46]. Briefly, a propensity model was developed using a logistic regression model with 
covariates (age, sex, and education) assigning each individual a propensity score that 
reflected his/her estimated probability of developing dementia, have all they been assessed 
for dementia an additional time after baseline. Based on the median of the propensity score 
of those that actually developed dementia a cutpoint was established. If the propensity score 
of participants who died without developing dementia were above the cutpoint, they were 
reclassified as an event and incidence of dementia recalculated.
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We fitted three types of regression models to estimate the effect of age, education, sex 
(female) and APOE-ε4 genotype on the incidence of dementia (all causes, AD and VaD). 
First, Cox proportional hazard regression models[47], in which participants who survived 
and remained dementia-free, as well as those who died without developing dementia, were 
treated as censored. Second, the modified Fine and Grey (FG) competing risks regression 
models that focus on cumulative incidence[45] were generated using the command stcrreg in 
STATA. Third, the FG models were generated after reclassification of individuals, i.e. 
participants who remained alive and dementia-free were again treated as censored, but those 
who died without developing dementia were treated either as competing risks (if their 
propensity scores were above the cutpoint) or as censored (if their propensity scores were 
below the cutpoint).”
Mean values of population parameters (± SD) were compared using the Mann-Whitney rank 
sum test, and p values ≤.05 were considered to be statistically significant. Statistical analyses 
were performed with Epi-Info 6.04b and SPSS version 23.0, 2016.
3. RESULTS
The mean age at baseline for study participants with longitudinal data was 66.3 years of age, 
and 69.5% of the study participants were women (Table 1). The study participants had, on 
average, 6 years of education and their mean MMSE was 23.7. The average number of 
follow-up visits by participants was 2.4 (range 2–5), and the time between the baseline and 
last assessments averaged 3.45 ± 3.05 years (Table 2). The mean age at first diagnosis of 
incident dementia was 75.1 ± 8.11 years. Table 1 provides statistics for individuals who did 
not participate in any follow-up evaluation due to death, relocation, refusal, or other cause. 
They were slightly older than those who did participate and included a smaller proportion of 
women. The nonparticipant group did not differ from participants with respect to years of 
education, APOE-ε4 genotype, or mean MMSE score obtained during the baseline 
evaluation.
Incidence of all dementia diagnoses was 9 cases per 1000 p-y for participants ≥55 years, and 
16 cases per 1000 p-y for participants ≥65 years. The incidence of dementia increased 
exponentially with age, reaching 91 cases per 1000 p-y for individuals 85 years or older 
(Table 3, Figure 2). The incidence of AD and VaD also increased with age (Table 3). AD 
accounted for 56% and VaD for 36% of all incident dementia cases with marginal cases of 
frontotemporal dementia, Lewy body disease, Parkinson’s with dementia, and dementia 
related to alcoholism. The incidence of all dementias, AD, and VaD was similar for men and 
women. The incidence of all dementias and AD was higher among APOE-ε4 carriers than 
noncarriers, but the presence of an APOE-e4 allele did not affect the incidence of VaD 
(Table 4).
In the sensitivity analyses, the age-specific incidence of dementia was recalculated to 
include nonparticipants, assuming that the nonparticipants had 1.5 to 5 times greater 
incidence of dementia than participants (Table A.1). As expected, the recalculated incidence 
was higher, particularly in the older groups, than when nonparticipants and participants were 
assumed to have the same incidence of dementia. When incidence was calculated using the 
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modified FG competing risks regression models, incidence was substantially higher than the 
unadjusted models (Table A.1), particularly in the older groups.
Results of the Cox models indicated that being older, female or a carrier of at least one 
APOE-ε 4 allele was associated with an increased incidence of dementia of all causes (Table 
A.2). However, only age and APOE-ε4 status were significant risk factors for AD, and only 
age was a risk factor for VaD. In undjusted models, low education level was not a significant 
risk factor for all dementias, AD, or VaD. After adjusting for death as competing risk, results 
were not radically changed, except for education, that became marginally significant for all-
cause dementia and VaD, but not for AD, and sex which became significant for the three 
dementia groups.
4. DISCUSSION
The MAS previously reported a high prevalence of dementia in the elderly population of 
Santa Lucia compared with other population-based studies in Latin America.[2] However, it 
was uncertain whether the high prevalence reflected a high incidence of dementia. We 
conducted an extensive follow-up evaluation of each participant by experienced local 
clinicians, using standardized full neuropsychological testing, neurological examination, and 
a multimodal examination of decline in activities of daily living. The results of the present 
longitudinal study confirm that age at onset of dementia is somewhat earlier than in US 
Whites [48] as evident by the relatively high incidence of dementia among MAS participants 
who are younger than 65 years of age. However, the incidence of dementia in those older 
than 65 years of age was comparable to other population-based data from other studies.[5–
10, 12] When adjusting for death as a competing risk for dementia, using a relative 
conservative approach, the resulting incidence per age group have not precedents. This 
finding suggests that dementia and death shared common risk factors, and once the 
development of public health sector and of medical science allows decreasing mortality 
rates, the magnitude of dementia rates could be much higher.
Consistent with the prevalence data, AD was the most frequent type of incident dementia. 
As expected, age, sex and APOE-ε4 were important risk factors for dementia. The average 
years of education was six years, which is consistent with the average years of schooling of 
adults in the Venezuela [49] for that age range, and was associated to dementia only when 
competing risks were considered. The mild significant association with education level 
could be due to the overall low level of education of the cohort.
The present study has several limitations. The primary limitation is that incidence rates were 
derived from a geographically restricted area and are not necessarily representative of all 
Venezuelans or Latin Americans. Moreover, our dementia diagnoses rely on extensive 
clinical evaluation but have not been autopsy confirmed by neuropathological evaluation. 
Thus, we may have underestimated subtypes of dementia, such as VaD and others. Unlike 
other community-based studies of dementia in developing countries, however, we were able 
to verify VaD using neuroimaging data because 67% of cases of dementia had 
neuroimaging. The high incidence of dementia might reflect anticipation of onset, more 
severe manifestation during early stages, or highly sensitive diagnoses. None of these 
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possibilities can be excluded in the present study. The Santa Lucia population lives in poor 
conditions relative to other populations in developed countries, including limited access to 
health care, which leads to high rates of uncontrolled co-morbidities such as systemic 
hypertension and diabetes. When compared with incidence rates among Caribbean 
Hispanics residing in northern Manhattan, the incidence of AD in the Santa Lucia cohort 
was higher (3.8% vs. 6.9% per 1000 p-y, respectively). Because both studies used similar 
diagnostic procedures and analytical methods, the possibility that there is a risk factor for 
AD specific to the MAS population cannot be ruled out.[50] However, most of the 
Caribbean Hispanics in the US study were from the Dominican Republic and Puerto Rico; 
few were from Venezuela. Finally, results of the sensitivity analysis indicate that the 
estimated incidence would have been higher if dementia-related incapacity, relocation, or 
death accounted for a significant proportion of nonparticipants, and modeling death as a 
competing risk of dementia revealed that the overall dementia rate could be twice as the 
unadjusted.
On the other hand, the present study has many strengths. This community-based study is as 
representative as possible of the population in the region, because all residents 55 years or 
older were invited to participate and the participation rate at baseline was higher than 75%.
[13] The nonparticipation rate in follow-ups, excluding death and relocation, was 
approximately 5%; thus, the probability that self-selection influenced the estimates of 
incidence is low. We used validated questionnaires and detailed neuropsychological 
instruments that provided extensive, in-depth clinical phenotyping. The diagnostic strategy 
and most of the health professionals involved in assessments were the same for the baseline 
and follow-up studies, thus minimizing assessment bias. The health professionals involved 
in the MAS diagnostic process included a psychiatrist, a geriatrician, and usually also a 
neurologist, all with specific training, expertise, and experience in dementia. Although 
‘diagnostic drift’ (the tendency to expand the parameters of a diagnosis leading to more 
diagnoses) cannot be excluded, cognitive performance cutoffs were established giving 
careful consideration to education level to minimize the possibility that the tests penalized 
individuals with lower education level and to ensure that the same diagnostic criteria were 
applied. The noted association between the APOE-ε4 genotype and the incidence of AD, but 
not VaD, further validates our results.
The present study provides the first estimates of the incidence of dementia, AD, and VaD for 
a population in the developing world that was not subject to a screening phase prior to 
assessment, and in which diagnoses were not paradigm-based, but the result of clinical 
consensus. The incidence of dementia, AD, and VaD in participants older than 65 years 
reported herein are comparable to the range of estimates previously reported for both 
developed [44, 51, 52] and developing [8–10, 12] countries (Figure 2). The incidence among 
those 55–64 years of age is quite high compared with studies in the developed world [48], 
and there is only one other reported study in the developing world for this age group, which 
took place in India and which also found lower rates than MAS.[5] However, direct 
comparisons to previous estimates of dementia incidence are difficult due to differences in 
the diagnostic methods, the age structure of the samples, and the use of different age strata in 
the analyses. We did not preselect individuals to be evaluated in depth by expert clinicians, 
to undergo extensive neuropsychological assessment, or for all participants to undergo 
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laboratory tests. Previous incidence studies of dementia in the developing world have 
carefully validated their methods, diagnostic strategies. We are building on their insight of 
the difficulties of carrying out this studies in low-resource settings, not only presenting data 
of Venezuela but also adding some methodological features. All previous incidence studies 
in the developing world [5–12] applied a screening phase to select those individuals who 
were more likely to be diagnosed as having dementia. Some used laboratory tests to evaluate 
physical health,[5, 9, 11] three obtained information on daily living activities from the 
participant and a proxy [7–10] and two included magnetic resonance imaging of the brain.[5, 
11] Only other study reported using a consensus conference of multidisciplinary health 
professionals to reach a diagnosis for all participants.[9]
The incidence rates reported herein would have been even higher if participants with a CDR 
of 0.5 were counted as having dementia and if competing risk analyses account for those 
individuals that die before a diagnosis of dementia is actually recorded in the study.. Thus, 
methodology can have a significant effect on estimates of incidence, and the wide range of 
incidence estimates in previous studies might reflect differences in methodology as much as 
actual differences in the incidence of dementia.
In summary, an accurate estimated incidence of dementia in the population of Maracaibo, 
Venezuela, showed fairly high rates in those younger than 65 years, and rates comparable to 
previous estimates in those older than 65 years for other countries. The wide range among 
previous estimates might be at least partly attributable to variation in methodology. Although 
the incidence of dementia was highest among the most elderly MAS participants, the impact 
is more important for relatively young individuals (55–64 years) who contribute to the 
economic support of their families, which are typically multigenerational and poor. 
Although AD had the highest incidence of the subtypes of dementia, VaD also had a 
relatively high incidence. Unlike AD, VaD currently offers significant opportunities for 
prevention. Although extrapolation to other Latin American countries or to Hispanic 
populations living in developed countries is not straightforward, the relatively high incidence 
of dementia reported here is of concern, especially given life expectancy in these developing 
countries has been increasing significantly. The burden on the health care system is likely to 
be notable when health care resources are limited.
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RESEARCH IN CONTEXT
1. Systematic review
We reviewed the literature using PubMed and reference lists from relevant articles. 
Studies of incidence of dementia in developing countries and in particular, in Latin 
America are scarce. We identified several publications on subjects older than 65 y, but 
none among younger than 65 and residing in a Latin American country.
2. Interpretation
Studies have shown that overall prevalence of dementia in Latin Americas as high as in 
developed countries. We extend research of epidemiology of dementia by including a 
population-based incidence study and including individuals 55 y or older. We found that 
compared with Whites in the US, this Latin American population has high incidence in 
55 – 64 age group, and intermediate incidence in older than 65y.
3. Future directions
As incidence of dementia is higher than expected in the relatively young segment of this 
Hispanic population, uncovering the risk factors and understanding the mechanisms for 
the higher risk of dementia is important. The possibility that the reported higher 
incidence is not only limited to this population of Venezuelans, but is also the case for 
Hispanics living in their country of origin or in other countries warrant extending 
epidemiological studies in Hispanics to a minimum of 55 years of age.
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Figure 1. 
Flow diagram showing numbers and percentages of Maracaibo Aging Study (MAS) 
participants included in the baseline and follow-up assessments and incidence estimates.
Maestre et al. Page 13
Alzheimers Dement. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Incidence of dementia vs. mean age reported herein for the Maracaibo Aging Study (MAS, 
Venezuela) and for comparison purposes, in six previous studies: Brazil = Catanduva, Brazil 
Study [9]; China = Anhui Cohort Study [6]; EURODEM = European Studies of Dementia 
(Denmark, France, Netherlands, United Kingdom) [52]; Latin America 10/66 (Dominican 
Republic, Peru, Venezuela) [10]; Mexico = Mexican Health and Aging Study [8]; and 
Rochester = Rochester, MN, Study (USA).[48]
Maestre et al. Page 14
Alzheimers Dement. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Maestre et al. Page 15
Ta
bl
e 
1
D
em
og
ra
ph
ic
 c
ha
ra
ct
er
ist
ic
s (
me
an
±S
D)
 of
 pa
rti
cip
an
ts 
in 
the
 ba
sel
ine
 an
d f
oll
ow
-u
p 
as
se
ss
m
en
ts 
of
 th
e 
M
ar
ac
ai
bo
 A
gi
ng
 S
tu
dy
.
N
= 
22
54
Su
bje
cts
 w
ith
 on
ly 
ba
sel
ine
 as
ses
sm
en
t
Su
bje
cts
 w
ith
 ≥1
 fo
llo
w
-u
p 
as
se
ss
m
en
t
p 
v
a
lu
e
D
ea
d 
n=
23
2
R
el
oc
at
ed
 n
=1
79
R
ef
us
ed
 n
=1
22
O
th
er
 n
=2
8
A
ll 
n=
56
1
n
=
16
93
A
ge
 a
t b
as
el
in
e,
 y
 ±
 S
D
70
.6
±9
.7
0
65
.9
±8
.2
1
65
.0
±7
.4
5
65
.5
±8
.2
0
67
.6
±9
.0
5
66
.3
±8
.2
5
.
05
W
o
m
en
, 
n
 (%
)
13
0(5
6.0
)
11
3(6
3.1
)
64
(53
.5)
19
 (6
7.9
)
32
6 
(58
.1)
11
77
.(6
9.5
)
<
.0
01
Ye
ar
s 
o
f f
or
m
al
 e
du
ca
tio
n,
 y,
 
m
ea
n
 ±
 S
D
5.
52
±4
.5
1
6.
83
±4
.5
6
6.
61
±4
.1
1
4.
82
±3
.4
6
6.
14
±4
.4
3
5.
87
±4
.1
1
.
75
A
ny
 A
PO
E-
ε4
, n
 (%
)
43
(18
.1)
22
(12
.3)
16
(13
.1)
7 
(25
.0)
88
 (1
5.7
)
31
1 
(21
.0)
.
09
M
M
SE
 sc
or
e,
 m
ea
n 
± 
SD
21
.5
±1
1.
2
24
.2
±4
.0
9
24
.2
±3
.6
9
23
.0
±6
.6
2
23
.0
±7
.9
4
23
.7
±4
.1
9
.
08
A
bb
re
v
ia
tio
ns
: A
PO
E-
ε4
 =
 A
lle
le
 ε4
 o
f t
he
 A
po
lip
op
ro
te
in
 E
; M
M
SE
 =
 M
in
i M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n 
(18
); 
SD
 = 
sta
nd
ard
 de
v
ia
tio
n.
p 
in
di
ca
te
s t
he
 si
gn
ifi
ca
nc
e 
of
 th
e 
di
ffe
re
nc
e 
be
tw
ee
n 
su
bje
cts
 w
ith
 on
ly 
the
 ba
sel
ine
 as
ses
sm
en
t a
nd
 th
ose
 w
ith
 ≥1
 fo
llo
w
-u
p 
as
se
ss
m
en
t.
Alzheimers Dement. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Maestre et al. Page 16
Table 2
Characteristics of participants in the Maracaibo Aging Study.
Non-Demented
CDR<1
n=1620
Demented
CDR≥1
n=73 All p value
Mean baseline age, y ± SD 65.6±7.89 75.1±8.11 66.3±8.25 <.001
Mean last follow-up age, y ± SD 70.5±8.39 82.6±6.44 70.96±8.60 <.001
Women, n (%) 1127 (69.6) 50 (68.4) 1177 (69.5) <.86
Years of formal Education ± SD 6.17±4.07 4.08 ± 3.69 5.87±4.11 <.001
Baseline MMSE score ± SD 23.9±4.00 19.4±4.71 23.65±4.19 <.001
Last MMSE score ± SD 23.4+4.24 14.0+5.59 23.08±4.62 <.001
APOE-ε4, % (3/4+4/4+2/4) 291(18.0) 20 (27.4) 311 (21.04) 0.02
Duration of follow-up, y ± SD 4.74±2.56 5.49±3.26 4.78±2.60 <.001
Abbreviations: APOE-ε4 = Allele ε4 of the Apolipoprotein E; MMSE = Mini Mental State Examination (18); CDR = Clinical Dementia Rating 
Scale (30); SD = standard deviation.
p indicates the difference between subjects by dementia status.
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Table 3
Incidence of all dementia diagnoses, Alzheimer’s disease, and vascular dementia for different age groups of 
the Maracaibo Aging Study population.
Age group Cases Person-Years Incidence/1000 p-y (95% CI)
Dementia
55–64 6 3796 1.58 (0.58–3.44)
65–74 33 3014 10.95 (7.54–15.4)
75–84 22 1084 20.30 (12.7–30.7)
85+ 12 132 90.90 (47.0–159)
All ages 73 8026 9.10 (7.13–11.4)
Women, all ages 50 5699 8.77 (6.51–11.6)
Men, all ages 23 2328 9.88 (6.26–14.8)
≥ 60 71 5885 12.06
≥ 65 67 4230 15.84
Standardized incidence 11.531
10.722
Alzheimer’s disease
55–64 3 3784 0.79 (0.16–2.32)
65–74 19 2962 6.42 (3.86–10.02)
75–84 12 1055 11.37 (5.88–19.87)
85+ 7 115 60.87 (24.47–125.41)
All ages 41 7916 5.18 (3.72–7.03)
Women, all ages 29 5618 5.16 (3.46–7.41)
Men, all ages 12 2298 5.22 (2.7–9.12)
≥ 60 39 5775 6.75
≥ 65 38 4132 9.20
Standardized incidence 6.971
6.422
Vascular dementia
55–64 3 3772 0.8 (0.16–2.32)
65–74 11 2875 3.83 (1.91–6.85)
75–84 9 1012 8.89 (4.07–16.88)
85+ 3 98 30.61 (6.31–89.46)
All ages 26 7757 3.35 (2.19–4.91)
Women, all ages 17 5495 3.09 (1.8–4.95)
Men, all ages 9 2262 3.98(1.82–7.55)
≥ 60 26 5631 4.62
≥ 65 23 3985 5.77
Standardized incidence 4.361
4.092
Abbreviations: p-y = person-years; CI = confidence intervals.
1Age-standardized incidence based on the age structure of the Venezuelan population [42].
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2Age-standardized incidence based on the age structure of the world population [43].
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Table 4
Incidence of all dementia diagnoses, Alzheimer’s disease, and vascular dementia for carriers and non-carriers 
of the APOE-ε4 allele.
APOE-e4 status Cases Person-Years Incidence/1000 p-y (95% CI)
Dementia
Carrier of APOE-ε4 20 1477 13.50 (8.27–20.9)
Non-carrier of APOE-ε4 51 5658 9.01 (6.70–11.8)
Alzheimer’s disease
Carrier of APOE-ε4 13 1448 8.98 (4.78–15.4)
Non-carrier of APOE-ε4 27 5581 4.84 (3.19–7.04)
Vascular dementia
Carrier of APOE-ε4 5 1373 3.64 (1.18–8.50)
Non-carrier of APOE-ε4 20 5494 3.64 (2.22–5.62)
Abbreviations: APOE-ε4 = Allele ε4 of the Apolipoprotein E; p-y = person-years; CI = confidence intervals.
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